# US 2023/0414956 A1 · Methods For Treating Diabetes With Alternating Electric Fields

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2023/0414956 A1
- Document ID: US20230414956A1
- Status: Published application
- Kind: A1
- Application number: 18/342,303
- Filed: 2023-06-27
- Published: 2023-12-28
- Earliest claimed: 2022-06-27
- Applicants: Novocure GmbH
- Inventors: Tali Voloshin-Sela; Lilach Avigdor
- Web page: https://patentgrep.com/patent/US20230414956A1

## CPC

- A61N 1/40: Applying electric fields by inductive or capacitive coupling (microwave apparatus A61N5/00); {Applying radio-frequency signals}
- A61N: ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY (measurement of bioelectric currents A61B; surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body A61B18/00; anaesthetic apparatus in general A61M; incandescent lamps H01K; infrared radiators for heating H05B)

## Abstract

Disclosed are methods of treating that can be performed using alternating electric fields applied in a single direction or multiple directions. Disclosed are method of treating a subject having diabetes comprising applying alternating electric fields to a target site of the subject for a period of time, the alternating electric fields having a frequency and field strength, wherein FGF21 is increased in the subject.

## Claims

### Claim 1

A method of treating a subject having diabetes comprising applying an alternating electric field to a target site of the subject for a period of time, the alternating electric field having a frequency and field strength,
wherein FGF21 is increased in the subject.

### Claim 2

A method of treating a subject comprising: identifying a subject with diabetes, applying an alternating electric field to a target site of the subject for a period of time, the alternating electric field having a frequency and field strength,
wherein FGF21 is increased in the subject.

### Claim 3

A method of treating a subject comprising: identifying a subject with diabetes, wherein the subject has a target site that is identified as being tumor-free, applying an alternating electric field to the target site of the subject for a period of time, the alternating electric field having a frequency and field strength,
wherein FGF21 is increased in the subject.

### Claim 4

A method of treating a subject comprising: identifying a subject with diabetes, wherein the subject is also identified as being tumor-free, applying an alternating electric field to a target site of the subject for a period of time, the alternating electric field having a frequency and field strength,
wherein FGF21 is increased in the subject.

### Claim 5 (depends on 1, 2, 3, 4)

The method of any one of claims 1-4, wherein the target site comprises hepatocytes.

### Claim 6 (depends on 1, 2, 3, 4)

The method of any one of claims 1-4, wherein the target site is the subject's liver.

### Claim 7 (depends on 1, 2, 3, 4)

The method of any one of claims 1-4, wherein the target site is the subject's torso.

### Claim 8 (depends on 1, 2, 3, 4, 5, 6, 7)

The method of any one of claims 1-7, further comprising administering a diabetes therapeutic to the subject.

### Claim 9 (depends on 1, 2, 3, 4, 5, 6, 7, 8)

The method of any one of claims 1-8, wherein the subject is not diagnosed with liver cancer.

### Claim 10 (depends on 1, 2, 3, 4, 5, 6, 7, 8)

The method of any one of claims 1-8, wherein the subject is not diagnosed with a tumor.

### Claim 11 (depends on 8, 9, 10)

The method of any one of claims 8-10, wherein the diabetes therapeutic is administered prior to applying the alternating electric fields.

### Claim 12 (depends on 8, 9, 10)

The method of any one of claims 8-10, wherein the diabetes therapeutic is administered after applying the alternating electric fields.

### Claim 13 (depends on 8, 9, 10)

The method of any one of claims 8-10, wherein the diabetes therapeutic is administered simultaneously with applying the alternating electric fields.

### Claim 14 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13)

The method of any one of claims 1-13, wherein the frequency of the alternating electric fields is between 50 kHz and 10 MHz.

### Claim 15 (depends on 14)

The method of claim 14, wherein the frequency of the alternating electric fields is about 200 kHz.

### Claim 16 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15)

The method of any one of claims 1-15, wherein the field strength is between 0.5 V/cm and 10 V/cm.

### Claim 17 (depends on 16)

The method of claim 16, wherein the field strength is 1 V/cm.

### Claim 18 (depends on 8, 9, 10, 11, 12, 13, 14, 15, 16, 17)

The method of any one of claims 8-17, wherein the diabetes therapeutic is metformin, a sulfonylurea, a glinide, a thiazolidinedione, a GLP-1 receptor agonist, or an SGLT2 inhibitor.

### Claim 19 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18)

The method of any one of claims 1-18, wherein the subject having diabetes has type 2 diabetes.

### Claim 20 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19)

The methods of any of claims 1-19, wherein a magnetic field is not applied to the subject.

### Claim 21

A method of increasing FGF21 in a subject having diabetes comprising: applying an alternating electric field to a target site of the subject for a period of time, the alternating electric field having a frequency and field strength,
wherein FGF21 is increased in the subject.

### Claim 22

A method of increasing blood glucose uptake in a subject having diabetes comprising: applying an alternating electric field to a target site of the subject for a period of time, the alternating electric field having a frequency and field strength,
wherein FGF21 is increased in the subject.

### Claim 23

A method of increasing brain-derived neurotrophic factor (BDNF) in a subject having diabetes comprising: applying an alternating electric field to a target site of the subject for a period of time, the alternating electric field having a frequency and field strength,
wherein FGF21 and BDNF are increased in the subject.

### Claim 24

A method of treating a subject having diabetes comprising applying an alternating electric field to a target site of the subject for a period of time, the alternating electric field having a frequency and field strength,
wherein FGF21 is increased in the subject.

### Claim 25

A method of treating a subject comprising: identifying a subject with diabetes, applying an alternating electric field to a target site of the subject for a period of time, the alternating electric field having a frequency and field strength,
wherein FGF21 is increased in the subject.

### Claim 26

A method of treating a subject comprising: identifying a subject with diabetes, wherein the subject is also identified as being tumor-free, applying an alternating electric field to a target site of the subject for a period of time, the alternating electric field having a frequency and field strength,
wherein FGF21 is increased in the subject.

### Claim 27 (depends on 24, 25, 26)

The methods of any of claims 24-26, wherein a magnetic field is not applied to the subject.

### Claim 28 (depends on 21, 22, 23, 24, 25, 26, 27)

The method of any of claims 21-27, wherein the target site comprises hepatocytes.

### Claim 29 (depends on 21, 22, 23, 24, 25, 26, 27, 28)

The method of any one of claims 21-28, wherein the target site is the subject's liver.

### Claim 30 (depends on 21, 22, 23, 24, 25, 26, 27, 28, 29)

The method of any one of claims 21-29, wherein the target site is the subject's torso.

### Claim 31 (depends on 21, 22, 23, 24, 25, 26, 27, 28, 29, 30)

The method of any one of claims 21-30, further comprising administering a diabetes therapeutic to the subject.

### Claim 32 (depends on 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31)

The method of any one of claims 21-31, wherein the subject is not diagnosed with a tumor of the liver.

### Claim 33 (depends on 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31)

The method of any one of claims 21-31, wherein the subject is not diagnosed with a tumor.

### Claim 34 (depends on 31, 32, 33)

The method of any one of claims 31-33, wherein the diabetes therapeutic is administered prior to applying the alternating electric fields.

### Claim 35 (depends on 31, 32, 33)

The method of any one of claims 31-33, wherein the diabetes therapeutic is administered after applying the alternating electric fields.

### Claim 36 (depends on 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33)

The method of any one of claims 21-33, wherein the diabetes therapeutic is administered simultaneously with applying the alternating electric fields.

### Claim 37 (depends on 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36)

The method of any one of claims 21-36, wherein the frequency of the alternating electric fields is between 50 kHz and 10 MHz.

### Claim 38 (depends on 37)

The method of claim 37, wherein the frequency of the alternating electric fields is about 200 kHz.

### Claim 39 (depends on 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38)

The method of any one of claims 21-38, wherein the field strength is between 0.5 V/cm and 10 V/cm.

### Claim 40 (depends on 39)

The method of claim 39, wherein the field strength is 1 V/cm.

### Claim 41 (depends on 31, 32, 33, 34, 35, 36, 37, 38, 39, 40)

The method of any one of claims 31-40, wherein the diabetes therapeutic is metformin, a sulfonylurea, a glinide, a thiazolidinedione, a GLP-1 receptor agonist, or an SGLT2 inhibitor.

### Claim 42 (depends on 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41)

The method of any one of claims 21-41, wherein the subject having diabetes has type 2 diabetes.

### Claim 43 (depends on 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42)

The methods of any of claims 21-42, wherein a magnetic field is not applied to the subject.
